Rocket Pharma

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The firm's clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded on July 7, 1999 and is headquartered in Cranbury, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector and adeno-associated viral vector gene therapy platforms. Its clinical program is an LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded on July 7, 1999 and is headquartered in Cranbury, NJ.

Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A501 Gene Therapy for Danon Disease

The mean of analysts' price targets for Rocket Pharmaceuticals (RCKT) points to a 163.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Think Rocket Pharmaceuticals (RCKT) Could Surge 163.35%: Read This Before Placing a Bet

Rocket Pharmaceuticals (RCKT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Rocket Pharmaceuticals (RCKT) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Arvinas Inc

Xencor

Health care stocks are trying to make a comeback and these three small-cap biopharma companies are leading the charge in some ways.

3 Small-Cap Biopharma Stocks that Could See Big Growth in 2023

CRANBURY, N.J.--( BUSINESS WIRE )--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today announces the addition of RP-A601 to Rocket's cardiac gene therapy portfolio as well as anticipated highlights for the year ahead across the Company's world-class pipeline of lentiviral and AAV gene therapy programs targeting rare hematologic and cardiovascular diseases. These announcements and anticipated highlights will be presented at the 41st Annual J.P. Morgan Healthcare Conference today at 2:15 p.m. PT by Gaurav Shah, M.D., Chief Executive Officer, Rocket Pharma.

Rocket Pharmaceuticals Expands Cardiac Gene Therapy Portfolio with Addition of RP-A601 for PKP2-ACM and Announces Positive Updated Phase 1 Data for RP-A501 in Danon Disease

The consensus price target hints at a 170.9% upside potential for Rocket Pharmaceuticals (RCKT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Believe Rocket Pharmaceuticals (RCKT) Could Rally 170.92%: Here's is How to Trade

CRANBURY, N.J.--( BUSINESS WIRE )--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today announces that Gaurav Shah, M.D., Chief Executive Officer, is scheduled to present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023, at 2:15 p.m. PT.

Rocket Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference

CRANBURY, N.J.--( BUSINESS WIRE )--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today announces updates from the Company's end-of-Phase 1 meeting with the U.S. Food and Drug Administration (FDA) regarding RP-A501, the Company's investigational adeno-associated virus (AAV)-based gene therapy for Danon Disease. During the meeting, Rocket reviewed the positive Phase 1 dataset with the FDA and proposed a study design and endpoints for ongoing clinical development of the investigational gene therapy.

Rocket Pharmaceuticals Provides Update on Anticipated Registration Path for RP-A501 in Danon Disease Following End-of-Phase 1 FDA Meeting

Axsome Therapeutics

Denali Therapeutics

Fate Therapeutics

Chart Industries

Karuna Therapeutics Inc

Analysts say a tough 2022 has left these small-cap stocks priced for outperformance in the new year and beyond.

7 Best Small-Cap Stocks to Buy for 2022 and Beyond

CRANBURY, N.J.--( BUSINESS WIRE )--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today announces positive clinical data from its lentiviral (LV)-based gene therapy programs at the 64th American Society of Hematology (ASH) Annual Meeting, taking place in New Orleans, Louisiana, from December 10-13.

Rocket Pharmaceuticals Presents Positive Clinical Data from Fanconi Anemia, Pyruvate Kinase Deficiency and Severe Leukocyte Adhesion Deficiency-I Programs at the 64th American Society of Hematology (ASH) Annual Meeting

Renovacor

CRANBURY, N.J.--( BUSINESS WIRE )--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today announces that it has completed the previously announced acquisition of Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases. Under the terms of the merger agreement entered into on September 19, 2022, Renovacor shareholders received, for each share of Renovacor common stock, 0.1763 shares of Rocket common stock.

Rocket Pharmaceuticals Completes Acquisition of Renovacor

A Rocket Pharmaceuticals, Inc. regulatory filing to the FDA of LV RP-L201 for Leukocyte Adhesion Deficiency-I is expected in the 1st half of 2023. A regulatory filing to the FDA of LV RP-L102 for Fanconi Anemia is expected in the 2nd half of 2023.

Rocket Pharmaceuticals: 2 Regulatory Filings In 2023 Could Propel It Higher

CRANBURY, N.J.--( BUSINESS WIRE )--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today announces that Gaurav Shah, M.D., Chief Executive Officer, will participate in a fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on Tuesday, November 29, 2022, at 3:30 p.m. ET.

Rocket Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference

Shares of gene therapy concern Rocket Pharmaceuticals have fallen 75% from their all-time high set in February 2021 with the only setback a three-month hold on one clinical trial. Although the company has conducted four secondaries since the onset of 2019, the recent secondary offering was the first dilutive event since its all-time high, save a small private placement.

Rocket Pharmaceuticals: Intriguing Potential

NEW ORLEANS , Nov. 3, 2022 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

RENOVACOR INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Renovacor, Inc. - RCOR

Rocket Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Progress

Rocket Pharmaceuticals Announces Presentations Highlighting AAV and Lentiviral Gene Therapies at Upcoming Scientific Congresses

The mean of analysts' price targets for Rocket Pharmaceuticals (RCKT) points to an 183.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts See an 184% Upside in Rocket Pharmaceuticals (RCKT): Can the Stock Really Move This High?

Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral Gene Therapies at the 29th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)

The mean of analysts' price targets for Rocket Pharmaceuticals (RCKT) points to a 211.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Does Rocket Pharmaceuticals (RCKT) Have the Potential to Rally 212% as Wall Street Analysts Expect?

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today announced that Raj Prabhakar, M.B.A., Chief Business Officer, will deliver an in-person company presentation at the 2022 Cell & Gene Meeting on the Mesa on Tuesday, October 11, at 2:30 p.m. PT in Carlsbad, CA. A live audio webcast of the presentat

Rocket Pharmaceuticals to Present at the 2022 Cell & Gene Meeting on the Mesa

First Eagle Alternative Capital BDC Inc

STORE Capital

NEW YORK , Oct. 6, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: STORE Capital Corporation (NYSE: STOR)'s  sale to GIC and funds managed by Oak Street for $32.25 per share in cash. If you are a STORE Capital shareholder, click here to learn more about your rights and options.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates STOR, RCKT, RCOR, FCRD

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of investigational genetic therapies for rare childhood disorders with high unmet need, today announces positive clinical updates from its Phase 1 Danon Disease Trial for RP-A501 through an oral poster session at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022. This includes updated safety and efficac

Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial for RP-A501 in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage, clinical biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today announces that Gaurav Shah, M.D., Chief Executive Officer, will participate in a fireside chat at the Chardan 6th Annual Genetic Medicines Conference on Tuesday, Oct. 4, at 2:00 p.m. ET, at the Westin Hotel in New York City. Management will

Rocket Pharmaceuticals to Present at Chardan 6th Annual Genetic Medicines Conference

Equillium Inc

Metacrine

NEW YORK , Sept. 26, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Equillium, Inc. (NASDAQ: EQ) 's  merger with Metacrine Inc. If you are an Equillium shareholder, click here to learn more about your rights and options.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EQ, MTCR, STOR, RCKT

News for Rocket Pharma Stock (RCKT)